Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials

Cancer

Volumn 120, Issue 2, 2014, Pages 262-270

  Stavraka, Chara ^a   Pinato, David J ^a   Turnbull, Samantha J ^b   Flynn, Michael J ^b   Forster, Martin D ^b   O'Cathail, Sean M ^c   Babar, Sayed ^a   Seckl, Michael J ^c   Kristeleit, Rebecca S ^b   Blagden, Sarah P ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

albumin; outcome; phase 1 trial; prognostic score; survival

Indexed keywords

ALBUMIN; LACTATE DEHYDROGENASE; SODIUM;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; GYNECOLOGIC CANCER; HAMMERSMITH SCORE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SKIN CANCER; SURVIVAL PREDICTION; UROGENITAL TRACT CANCER; VALIDATION PROCESS; VERY ELDERLY;

EID: 84891851200     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28381     Document Type: Article

References (32)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, et al. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000; 18: 684-692.
2. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005; 352: 895-904.
3. Karavasilis V, Digue L, Arkenau T, et al. Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur J Cancer. 2008; 44: 978-982.
4. Ho J, Pond GR, Newman C, et al. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer. 2006; 6: 263.
5. Arkenau HT, Olmos D, Ang JE, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer. 2008; 44: 1536-1540.
6. Bachelot T, Ray-Coquard I, Catimel G, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol. 2000; 11: 151-156.
7. Yamamoto N, Tamura T, Fukuoka M, et al. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol. 1999; 15: 737-741.
8. Chau NG, Florescu A, Chan KK, et al. Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? BMC Cancer. 2011; 11: 426.
9. Penel N, Vanseymortier M, Bonneterre ME, et al. Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs. 2008; 26: 53-58.
10. Arkenau HT, Olmos D, Ang JE, et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008; 98: 1029-1033.
11. Fussenich LM, Desar IM, Peters ME, et al. A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer. 2011; 47: 1152-1160.
12. Penel N, Delord JP, Bonneterre ME, et al. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs. 2010; 28: 76-82.
13. Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009; 27: 2692-2696.
14. Olmos D, Ang JE, Gomez-Roca C, et al. Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase I oncology trial participants-Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase I cancer patients. Eur J Cancer. 2012; 48: 594-596.
15. Serkova NJ,. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat. 2011; 14: 224-235.
16. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001; 19: 265-272.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
18. Kaplan EL, Meier R,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
19. Cox DR,. Regression models and life tables. J Roy Stat Soc B. 1972; 34: 187-202.
20. Pencina MJ, D'Agostino RB,. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23: 2109-2123.
21. Harrell FE Jr,. Regression Modelling Strategies [computer program]. R package, version 3.0-0. http://cran.r-project.org/web/packages/rms/index.html; 2010.
22. Kurzrock R, Benjamin RS,. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med. 2005; 352: 930-932.
23. Seidenfeld J, Horstmann E, Emanuel EJ, et al. Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med. 2008; 168: 16-20.
24. Olmos D, A'Hern P, Marsoni S, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol. 2012; 30: 996-1004.
25. Garrido-Laguna I, Janku F, Vaklavas C, et al. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012; 118: 1422-1428.
26. Wheler J, Tsimberidou AM, Hong D, et al. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 2009; 115: 1091-1099.
27. Ploquin A, Olmos D, Lacombe D, et al. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer. 2012; 107: 1025-1030.
28. Olmos D, A'hern RP, Marsoni S, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol. 2012; 30: 996-1004.
29. Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001; 24: 547-550.
30. Feliu J, Jimenez-Gordo AM, Madero R, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst. 2011; 103: 1613-1620.
31. Colgan SM, Mukherjee S, Major P,. Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis. Clin Colorectal Cancer. 2007; 6: 442-446.
32. Scartozzi M, Giampieri R, Maccaroni E, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012; 106: 799-804.